U
ADMS

UBS’s Adamas Pharmaceuticals ADMS Stock Holding History

UBS’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$27K Buy
1,466
+832
+131% +$14.3K ﹤0.01% 7628
2014
Q2 		$12K Buy
+634
New +$11.4K ﹤0.01% 8718

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OTPPB
Ontario Teachers' Pension Plan Board Toronto, Ontario, Canada $3.46B AUM 7.79% 1-Year Est. Return
WSA
Wall Street Associates Lajolla, California $151M AUM 30.3% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
BS
Bow Street New York $52.4M AUM 2.22% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GPCM
Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

UBS's ADMS Position: Q3 2014 in Review

UBS increased its Adamas Pharmaceuticals (ADMS) stake by 131% in Q3 2014, buying an estimated $14.3K and bringing the position to 1,466 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #7628.

UBS first reported a position in ADMS in Q2 2014 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold ADMS as of Q3 2014.

  • UBS held 1,466 shares of Adamas Pharmaceuticals worth $27K as of Q3 2014.
  • UBS bought 832 Adamas Pharmaceuticals shares in Q3 2014, an estimated $14.3K.
  • Adamas Pharmaceuticals made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7628 holding.
  • UBS first reported a position in Adamas Pharmaceuticals in Q2 2014 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.